The expression patterns and functional roles of miRNAs in retinoblastoma (RB) are poorly understood, especially those involved in chemoresistance. Here, we validated the expression pattern of 20 potential RB-suppressive miRNAs and confirmed that miR-184 is the most significantly decreased miRNA in human RB tissues, as well as chemoresistant cell line. Bioinformatic and molecular analyses revealed that SLC7A5 has three binding sites of miR-184 and significantly increased in RB tissues. miR-184 negatively correlated with SLC7A5 expression in RB tissues and mainly target position 2494-2513 of the SLC7A5 3 ' UTR to inhibit its expression. Furthermore, enforced expression of miR-184 reversed the oncogenic roles of SLC7A5 on proliferation, migration, and invasion of RB cells. In addition, miR-184 also enhances chemosensitivity of RB cells via inducing apoptosis and G2/M cell cycle arrest. Molecular studies revealed that miR-184-decreased phosphorylation status of known DNA damage repair sensors of the ATR/ATM pathways and induced persistent formation of gamma H2AX foci depend on targeting SLC7A5, leading to persistent DNA damage. Thus, targeting the miR-184/SLC7A5 pathway will provide new opportunities for drug development to reverse chemotherapeutic resistance in RB.
基金:
National Natural Science Foundation of China [81001067, 81372664]; Natural Science Foundation of Hubei Province, China [2018CFB463]
第一作者单位:[1]Tianjin Med Univ, Dept Ophthalmol, Gen Hosp, Tianjin, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
He Tian-Geng,Xiao Zi-Yun,Xing Yi-Qiao,et al.Tumor Suppressor miR-184 Enhances Chemosensitivity by Directly Inhibiting SLC7A5 in Retinoblastoma[J].FRONTIERS IN ONCOLOGY.2019,9:doi:10.3389/fonc.2019.01163.
APA:
He, Tian-Geng,Xiao, Zi-Yun,Xing, Yi-Qiao,Yang, Hua-Jing,Qiu, Hong&Chen, Jian-Bin.(2019).Tumor Suppressor miR-184 Enhances Chemosensitivity by Directly Inhibiting SLC7A5 in Retinoblastoma.FRONTIERS IN ONCOLOGY,9,
MLA:
He, Tian-Geng,et al."Tumor Suppressor miR-184 Enhances Chemosensitivity by Directly Inhibiting SLC7A5 in Retinoblastoma".FRONTIERS IN ONCOLOGY 9.(2019)